INREBIC (fedratinib) capsules, for oral use. Initial U.S. Approval: 2019

INREBIC (fedratinib) capsules, for oral use. Initial U.S. Approval: 2019

INREBIC is a kinase inhibitor indicated for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemiavera or post-essential thrombocythemia) myelofibrosis (MF).
Capsules: 100 mg
Manufactured By: Celgene Corporation
Prescribing Information URL: Click Here

Access to INREBIC ® (fedratinib) capsules: Anticancer drugs available upon request. To get best price please share your mobile number to receive quotes from Medvitaz Pharma Solutions.

Fedratinib (trade name Inrebic), used in the form of fedratinib hydrochloride, is an orally available semi-selective inhibitor of Janus kinase 2 (JAK-2) developed for the treatment of patients with myeloproliferative diseases including myelofibrosis.


There are no reviews yet.

Add a review

Neeraj Nagpal

Head of Operations

 The profound knowledge of more than 20 years in sales and marketing sector, he has been working dedicatedly and contributing to pharmaceuticals industry. He handles all operations over the country.

Contact Our Team

Contact us and we will reply as soon as possible!

    need help?

     MEDVITAZ is an initiative for helping end-users directly to get the right medicines and right medical treatments from the right source.